Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
Download the Pharmacy booklet which is a guide to treatment with MYLOTARG. Summary of Product Characteristics (SmPC) should be consulted for full guidance
Please view MYLOTARG SmPC for more information
Download the Fast Facts PDF document to aid your understanding of MYLOTARG
Download Fast Facts Guide
For additional adminstration information on use in pregnancy, pre-medication, light sensitivity and monitoring during infusion, please click here
Additional admin info
SmPC, Summary of Product Characteristics
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
Dosing Guide
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No